Ultime notizie per Vigil Neuroscience (NASDAQ:VIGL) Azioni

Vigil Neuroscience

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

Vigil Neuroscience Inc

Zscaler Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) will be reporting its first-quarter earnings on Monday. Wall Street expects 63 cents in EPS and $606.20 million in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=ZS" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 2.56% over the past year, 24.69% over the past six months.
Let&#8217;s look at what the charts indicate for Zscaler stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/insights/news/24/10/41275602/heres-how-much-you-would-have-made-owning-zscaler-stock-in-the-last-5-years">Here&#8217;s How Much You Would Have Made Owning Zscaler Stock In The Last 5 Years</a>
<h2 class="wp-block-heading">Zscaler Shows Moderately Bullish Trend Ahead Of Q1 Earnings</h2>
Zscaler is showing a moderately bullish trend ahead of its earnings, although slight selling pressure is evident. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29085738/Screenshot-2024-11-29-at-7.19.46-PM.png" alt="" class="wp-image-670173" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29085738/Screenshot-2024-11-29-at-7.19.46-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29085738/Screenshot-2024-11-29-at-7.19.46-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112924&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The stock price of $204.96 is hovering just below its eight-day simple moving average (SMA) of $206.77, which signals some near-term resistance. 
However, Zscaler stock is trading above key support levels, with the 20-day SMA at $201.27, the 50-day SMA at $189.44, and the 200-day SMA at $187.77, all suggesting a bullish long-term outlook. 
The moving average convergence/divergence (MACD) indicator is also positive at 5.39, reinforcing the overall bullish sentiment. 
The relative strength index (RSI) of 57.45 shows Zscaler stock is not yet overbought, indicating room for potential upside as it prepares for earnings.&nbsp;
<h2 class="wp-block-heading">Zscaler Analysts See 17% Upside</h2>
Zscaler Analysts Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/ZS/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Zscaler stock stands at a Buy currently with a price target of $219.85. Analysts from BTIG, Jefferies and Keybanc set an average price target of $242.67 for Zscaler stock, implying a 17.37% upside.
ZS Price Action: Zscaler stock was up 0.7% to $206.41 at the time of publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/11/41935528/top-4-tech-stocks-that-may-keep-you-up-at-night-this-quarter">Top 4 Tech Stocks That May Keep You Up At Night This Quarter</a></li>
</ul>
Photo: Shutterstock

Technicals

Tech

Trading Ideas

Zscaler Signals Strength With Positive Indicators Ahead Of Monday's Earnings

Jefferies analyst Omar Nokta maintains Nordic American Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAT#NYSE">NAT</a>) with a Hold and maintains $3.5 price target.

News

Price Target

Analyst Ratings

Jefferies Maintains Hold on Nordic American Tankers, Maintains $3.5 Price Target

JP Morgan analyst Brian Essex maintains SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) with a Overweight and raises the price target from $30 to $33.

JP Morgan Maintains Overweight on SentinelOne, Raises Price Target to $33

Many Americans will likely shop or place online orders this Black Friday. But National Football League fans will give thanks that there is another <a href="https://www.benzinga.com/topic/black-friday">football game to watch</a>.
What Happened: Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) looking to cash in on <a href="https://www.benzinga.com/topic/thursday-night-football">extra viewership</a> for the second straight year when Prime Video airs a <a href="https://www.benzinga.com/topic/nfl">Black Friday NFL game</a>.
On Friday, the Las Vegas Raiders (2-9) take on the Kansas City Chiefs (10-1) in Kansas City. The game streams exclusively on Prime Video.
While the teams don't have similar records and the game has the largest spread for an expected dominant performance for the Chiefs, Amazon hopes viewers will tune in.
Sportsbook DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) lists the betting spread as the Chiefs favored by 13.5 points. Of the NFL's Week 13 matchups, that&#8217;s the biggest spread. The Chiefs are 10-1 on the season as one of the top teams, but have been winning games close.
The Chiefs are 5-6 against the spread on the season, meaning they win games, but not by the margins expected by sportsbooks. Earlier this season, the Chiefs beat the Raiders 27-20.
Amazon is the exclusive home of "Thursday Night Football" games and viewership for the 2024 season is averaging 13.3 million for those contests, up 8% year-over-year, as reported by <a href="https://www.sportico.com/business/media/2024/nfl-amazon-black-friday-commericial-ad-cost-1234817640/">Sportico</a>.
Last year's Black Friday NFL game saw the Miami Dolphins defeat the New York Jets 34-13 with an average of 9.61 million people watching, less than the average for "Thursday Night Football" games at the time.
Items helping Amazon could be a minimal slate of sports content early Friday with the game set to kickoff at 3 p.m. ET and the fact that the Chiefs are in the game.
The Chiefs are America's most watched team in 2024 with eight national TV games averaging 24.2 million viewers this season.
While no NFL team has won three consecutive Super Bowls, the Chiefs are looking to be the first and have been among the top favored teams at sportsbooks. Back in February, the Chiefs ranked second in Super Bowl LIX odds at +650. The Chiefs moved to first throughout the 2024 season, but now rank second at +475 to the Detroit Lions (+260) who now hold an NFL best 11-1 record the Chiefs will hope to tie Friday.
Read Also: <a href="https://www.benzinga.com/general/sports/24/11/42226470/heres-why-the-detroit-lions-dallas-cowboys-always-have-thanksgiving-day-nfl-games">Here&#8217;s Why The Detroit Lions, Dallas Cowboys Always Have Thanksgiving Day NFL Games</a>
Why It Matters: Amazon could gain subscribers for Prime or the standalone Prime Video streaming platform membership.
Amazon is also set to get a boost to its advertising revenue thanks to the strong demand for live sports content. Amazon charged up to $750,000 per 30-second advertisement. The company averaged $565,000 for its ad rates, which among NFL coverage trails only "Sunday Night Football" on NBC and "Monday Night Football" on ESPN averages of $1 million and $665,000 respectively.
The e-commerce giant sold out of advertising inventory months ago and saw strong demand from newcomers who didn't advertise in last year's game and haven't advertised in this season's "Thursday Night Football" games.
Amazon has commanded a younger audience for its NFL games with an average age of 48.4 compared to a national average of 55.4 and a broadcast average of 63.0.
Advertisers and Amazon will be hoping that trends from last year continue. In last year's Black Friday game, viewers were 78% more likely to search for brands they saw advertise during the NFL game.
This could be good news for advertisers who include Ralph Lauren, Google Pixel, Uber Eats, Solo Stove and Microsoft, as reported by <a href="https://www.adweek.com/convergent-tv/brands-amazon-black-friday-nfl-game/">AdWeek</a>. 
QR codes shown during last year's Black Friday game had 350% higher engagement than during other NFL games.
Leading the way with QR codes will likely be Amazon itself who with the rights to the game can control how many ad spots they get and how often they put their own QR codes on screen hoping to take advantage of the viewers while non-sports fans are also shopping on the e-commerce site throughout the weekend.
Price Action: Amazon stock trades at $205.61 on Friday versus a 52-week trading range of $142.81 to $215.90. Amazon stock is up 37% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41664778/amazon-q3-earnings-highlights-revenue-beat-eps-beat-q4-guidance-new-kindles-significantly-outperfor">Amazon Q3 Earnings Highlights: Revenue Beat, EPS Beat, Q4 Guidance, New Kindles &#8216;Significantly Outperforming Our Expectations&#8217;</a></li>
</ul>
Image: Shutterstock

Sports Betting

Sports

AMZN

DKNG

Black Friday NFL Game Preview: Kansas City Chiefs Continue Path To Super Bowl Three-Peat, Amazon Looks For Holiday Sales Boost

Brazil has made a landmark move in the cannabis sector. In a pivotal decision, the Superior Court of Justice (STJ) ruled in favor of cultivating, processing and selling industrial hemp for <a href="https://www.benzinga.com/topic/medical-cannabis">medical and pharmaceutical uses</a>. This ruling opens the door to significant new opportunities for both domestic and international stakeholders in the global <a href="https://www.benzinga.com/cannabis">cannabis market</a>.
<h3 class="wp-block-heading">A Legal Battle Paves The Way</h3>
The ruling stems from a legal challenge presented by a company seeking to import hemp seeds and cultivate them for medical purposes. The company faced resistance from Brazil's national health regulatory agency, ANVISA, due to the country's strict cannabis laws. As <a href="https://hemptoday.net/court-backs-medical-cbd-production-in-brazil-but-bypasses-industrial-applications/">reported</a> by Hemp Today, this legal battle played a crucial role in bringing the issue to the forefront of Brazil's legislative agenda.
While the ruling is a significant victory for the medical cannabis community, Justice Regina Helena Costa emphasized that the court&#8217;s decision was limited to health-related applications. "The examination of the controversy should be limited to the feasibility of importing hemp seeds and subsequent cultivation to meet demands involving the right to health," she noted, underlining the narrow focus of the case.
<h3 class="wp-block-heading">A Booming Market</h3>
Brazil, with a population of more than 200 million and an increasingly favorable attitude toward cannabis-based treatments, stands to become a major player in the global medical cannabis industry. Industry experts estimate that the medical cannabis market in Brazil <a href="https://www.statista.com/outlook/hmo/cannabis/medical-cannabis/brazil">will reach $185 million</a> this year, with <a href="https://www.benzinga.com/topic/cbd">CBD products</a> dominating the landscape. These products are favored for their broader applications and the fact that they are subject to less stringent regulatory restrictions compared to <a href="https://www.benzinga.com/topic/thc">THC</a>.
<h3 class="wp-block-heading">Key Takeaways From The Ruling</h3>
The STJ's ruling clarifies an important legal distinction: industrial hemp, defined as cannabis with a THC content below 0.3%, is not classified as a controlled substance. This means that hemp can now be legally cultivated and sold for medical and pharmaceutical uses, but cannot be used for any other purpose, ensuring the focus remains on health-related applications.
However, the ruling did not address the full spectrum of potential uses for industrial hemp, such as in textiles, construction materials and biofuels. The decision primarily addressed the medical cannabis aspect, and the Brazilian government remains in control of all cannabis regulations, including those for industrial hemp.
Moving forward, ANVISA will need to align its regulations with the Narcotics Act to allow for the importation of hemp seeds and to regulate hemp cultivation. Additionally, the government is tasked with developing safeguards to prevent misuse and maintain the safety and integrity of the emerging hemp industry.
<h3 class="wp-block-heading">Industry Reactions And Future Prospects</h3>
The ruling has sparked a range of reactions within the cannabis industry. Lorenzo Rolim da Silva, president of the Latin American Industrial Hemp Association, expressed cautious optimism. "It was a historical moment for the Brazilian regulatory landscape for sure, but it wasn't all we hoped for," Rolim da Silva remarked.
Despite these reservations, the ruling sets a strong precedent for future regulatory developments. Many in the industry view it as a stepping stone toward broader legalization of industrial hemp, which could eventually unlock its potential in multiple sectors, from pharmaceuticals to construction.
<h3 class="wp-block-heading">The Road Ahead</h3>
The Brazilian government now has a six-month window to establish a comprehensive regulatory framework for industrial hemp. This framework will be crucial in determining the future of hemp cultivation in the country, addressing key issues such as licensing, product standards, and market access.
Cover image made with AI

Cannabis

Government

Latin America

Psychedelics

Regulations

Brazil Greenlights Hemp Production, Sale: A Game-Changer For Medical Cannabis

Hub Cyber Security Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBC#NASDAQ">HUBC</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Friday.</a>
The company has reached an agreement with AGP to reduce its $5.7 million convertible note obligations by 70%, signaling a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42244369/hub-cyber-security-reduces-5-7-million-debt-by-70-secures-additional-funding-plans-long-term-refin" rel="noreferrer noopener">significant reduction in its overall debt.</a>
This effort is part of Hub Cyber Security&#8217;s broader strategy to bolster its balance sheet and position itself for long-term success.
In addition, the company has secured an additional $1 million investment from a private investor who has previously committed a total of $10 million to the company.
This capital infusion will support the company&#8217;s growth and key initiatives heading into the end of the year. HUB Security is also in the process of refinancing another $7.5 million of debt into a long-term settlement, further strengthening its financial foundation.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/24/11/42244324/black-friday-frenzy-shoppers-queue-for-taylor-swift-merch-retro-gadgets-and-more-as-retailers-open-doors-early-amid-shortened-shopping-season" rel="noreferrer noopener">Black Friday Frenzy: Shoppers Queue For Taylor Swift Merch, Retro Gadgets And More As Retailers Open Doors Early Amid Shortened Shopping Season</a>
Also, the company stated that Renah Persofsky will join its Board of Directors, replacing Lior Lurye. Persofsky has served on multiple boards of both Nasdaq-listed and unlisted private companies and brings vast business experience.
&#8220;As we move forward, HUB Security remains steadfast in its mission to deliver exceptional value to our stakeholders, drive innovation in Secured Data Fabric solutions, and expand our leadership in the global cybersecurity landscape,&#8221; said Noah Hershcoviz, CEO of HUB Cyber Security.
Price Action: HUBC shares are trading higher by 4.29% to $0.5397 at last check Friday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42225423/mexico-president-claudia-sheinbaum-to-trump-neither-threats-nor-tariffs-will-solve-your-fentanyl-crisis?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Sheinbaum To Trump: ‘Neither Threats Nor Tariffs' Will Solve Your Fentanyl Crisis</a></li>
</ul>

Equities

Financing

Management

Markets

Movers

General

HUBC

Hub Cyber Security Powers Up: Major Debt Reduction, Fresh Investment, Board Change & More

Tomorrow&#8217;s Golf League (TGL), a new indoor golf league co-founded by Tiger Woods and Rory McIlroy, is set to launch in January 2025. The league counts the PGA Tour and SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) as partners to present what they call &#8220;golf remixed&#8221; and &#8220;a fusion of sports, tech, entertainment, media, <a href="https://www.benzinga.com/general/entertainment/22/08/28621740/tiger-woods-rory-mcilroy-unite-on-new-golf-league-can-it-compete-with-pga-golf-and-liv-golf">fan experience and interaction.&#8221;</a>
The Details: TGL's <a href="https://tglgolf.com/">first season</a> will kick off on Jan. 7, 2025, from the purpose-built SoFi Center venue in Palm Beach Gardens, Florida. Six teams of four PGA players representing different cities will compete in a 15-match regular season airing live on ESPN and ESPN+. 
TGL matches will feature large simulator screens and interactive elements that blend traditional golf with modern technologies including a 64-foot-by-53-foot simulator powered by Full Swing. Players will hit from areas with real grass, fairway, rough and sand into the screen for tee shots and approach shots and transition to a real green for shots of approximately 50 yards or less.
Each match is expected to last about two hours and will include elements like a shot clock and timeouts, offering a fast-paced experience for fans.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/retail-sales/24/11/42170721/thanksgiving-dinner-gobbles-up-19-more-cash-this-year-many-holiday-hosts-already-regret-their-decision">Thanksgiving Dinner Gobbles Up 19% More Cash This Year, Many Holiday Hosts &#8216;Already Regret Their Decision&#8217;</a>
Several PGA Tour players from TGL's New York Gold Cub team joined The Tonight Show with Jimmy Fallon this week to talk about the new league.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">.<a href="https://twitter.com/RickieFowler?ref_src=twsrc%5Etfw">@RickieFowler</a>, <a href="https://twitter.com/XSchauffele?ref_src=twsrc%5Etfw">@XSchauffele</a>, <a href="https://twitter.com/MattFitz94?ref_src=twsrc%5Etfw">@MattFitz94</a> &amp; Cameron Young set up <a href="https://twitter.com/TGL?ref_src=twsrc%5Etfw">@TGL</a>, the brand-new primetime golf league! <a href="https://twitter.com/hashtag/FallonTonight?src=hash&amp;ref_src=twsrc%5Etfw">#FallonTonight</a> <a href="https://t.co/6mqyXOsmKO">pic.twitter.com/6mqyXOsmKO</a>
&mdash; The Tonight Show (@FallonTonight) <a href="https://twitter.com/FallonTonight/status/1861278091881910318?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"TGL is the next evolution within professional golf, and I am committed to helping lead it into the future. Embracing technology to create this unique environment gives us the ability to move our sport into primetime on a consistent basis alongside so many of sports' biggest events," Woods said.
SoFi Tees Up: SoFi Technologies is the<a href="https://tglgolf.com/articles/2023/10/sofi-announced-as-tgl-presenting-sponsor-&amp;-venue-naming-rights-partner"> presenting sponsor </a>of the TGL golf league. The company's involvement also includes the naming rights to the SoFi Center, TGL's&nbsp; 250,000-square-foot dedicated venue, as well as the naming of the league's championship trophy, the SoFi Cup.&nbsp;
SoFi is also the naming rights partner of SoFi Stadium, home of the Los Angeles Chargers and the Los Angeles Rams in the NFL.
"To achieve our goal of becoming a top 10 financial institution, it's critical that we build brand awareness and trust with consumers to become a household name. Investing in sports has proven unequivocally valuable time and time again in helping us unlock this goal," SoFi CEO Anthony Noto said. 
"From our very first conversation, there's been a natural alignment between TGL's tech-forward approach with SoFi's approach as an unconventional financial services solution. We're thrilled to be partnering to bring SoFi Center and TGL to life," Noto added.&nbsp;
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/retail-sales/24/11/42225933/black-friday-cyber-monday-shopping-set-to-break-sales-records">Black Friday, Cyber Monday Shopping Set To Break Sales Records</a></li>
</ul>
Photo: <a href="https://creativecommons.org/licenses/by-sa/2.0">KA Sports Photos </a>from Hanover, MD, USA, CC BY-SA 2.0, via Wikimedia Commons

Fintech news covering the emerging Financial Technology services sector

Fintech

SOFI

Tiger Woods, Rory McIlroy, PGA Tour, SoFi Prep 'Golf Remixed' For 2025 TGL Launch

Offerings

PMEC

Primech Holdings Files For Mixed Shelf Of Up To $50M

JP Morgan analyst Detlef Winckelmann maintains Smurfit WestRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>) with a Overweight and raises the price target from $65 to $69.

JP Morgan Maintains Overweight on Smurfit WestRock, Raises Price Target to $69

Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 18% of the investors opened trades with bullish expectations and 63% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $1,196,435 and 2, calls, for a total amount of $1,384,310.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $22.5 and $105.0 for Moderna, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 3135.88 with a total volume of 4,381.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $22.5 to $105.0 over the last 30 days.
<h3>Moderna Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732895188_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$5.05</td>
<td>$4.8</td>
<td>$4.85</td>
<td>$50.00</td>
<td>$1.3M</td>
<td>1.5K</td>
<td>2.7K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$5.5</td>
<td>$4.95</td>
<td>$5.25</td>
<td>$30.00</td>
<td>$446.2K</td>
<td>1.4K</td>
<td>852</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.25</td>
<td>$11.4</td>
<td>$13.25</td>
<td>$55.00</td>
<td>$331.2K</td>
<td>4.7K</td>
<td>10</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$12.05</td>
<td>$11.85</td>
<td>$11.85</td>
<td>$50.00</td>
<td>$141.0K</td>
<td>4.0K</td>
<td>120</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$11.2</td>
<td>$11.15</td>
<td>$11.2</td>
<td>$50.00</td>
<td>$76.1K</td>
<td>112</td>
<td>1</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Moderna</h3>
<ul>
<li>Currently trading with a volume of 1,119,525, the MRNA's price is up by 0.14%, now at $43.45. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 83 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

MRNA

Moderna's Options: A Look at What the Big Money is Thinking

Whales with a lot of money to spend have taken a noticeably bullish stance on Hewlett Packard.
Looking at options history for Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 20% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $61,806 and 8, calls, for a total amount of $470,807.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $18.0 to $22.0 for Hewlett Packard during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Hewlett Packard's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Hewlett Packard's significant trades, within a strike price range of $18.0 to $22.0, over the past month.
<h3>Hewlett Packard Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732895183_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$3.4</td>
<td>$3.2</td>
<td>$3.3</td>
<td>$18.00</td>
<td>$132.0K</td>
<td>1.7K</td>
<td>400</td>
</tr>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$5.1</td>
<td>$4.8</td>
<td>$5.04</td>
<td>$20.00</td>
<td>$94.7K</td>
<td>135</td>
<td>200</td>
</tr>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.95</td>
<td>$0.85</td>
<td>$0.95</td>
<td>$21.50</td>
<td>$70.8K</td>
<td>250</td>
<td>3.0K</td>
</tr>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.95</td>
<td>$0.85</td>
<td>$0.95</td>
<td>$21.50</td>
<td>$49.6K</td>
<td>250</td>
<td>2.4K</td>
</tr>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.95</td>
<td>$21.50</td>
<td>$33.4K</td>
<td>250</td>
<td>990</td>
</tr>
</tbody>
</table>

<h3>About Hewlett Packard</h3>
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment; it also has a high-performance computing business. HPE's stated goal is to be a complete edge-to-cloud company. Its portfolio enables hybrid clouds and hyperconverged infrastructure. It uses a primarily outsourced manufacturing model and employs 60,000 people worldwide.
Having examined the options trading patterns of Hewlett Packard, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Hewlett Packard</h3>
<ul>
<li>Trading volume stands at 1,788,029, with HPE's price up by 2.0%, positioned at $21.21.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 6 days.</li>
</ul>
<h3>Expert Opinions on Hewlett Packard</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $26.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on Hewlett Packard, maintaining a target price of $23. 
&#x2A; In a positive move, an analyst from Raymond James has upgraded their rating to Strong Buy and adjusted the price target to $29. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Hewlett Packard options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Unpacking the Latest Options Trading Trends in Hewlett Packard

Deep-pocketed investors have adopted a bullish approach towards Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVNA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Carvana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 60% leaning bullish and 40% bearish. Among these notable options, 5 are puts, totaling $295,000, and 5 are calls, amounting to $205,854.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $240.0 and $305.0 for Carvana, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Carvana's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Carvana's substantial trades, within a strike price spectrum from $240.0 to $305.0 over the preceding 30 days.
<h3>Carvana Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732895178_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$43.45</td>
<td>$42.2</td>
<td>$43.45</td>
<td>$280.00</td>
<td>$91.2K</td>
<td align="right">146</td>
<td>21</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$43.15</td>
<td>$42.35</td>
<td>$43.15</td>
<td>$280.00</td>
<td>$81.9K</td>
<td align="right">146</td>
<td>40</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$5.85</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$260.00</td>
<td>$50.5K</td>
<td align="right">386</td>
<td>108</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$35.9</td>
<td>$32.9</td>
<td>$35.2</td>
<td>$300.00</td>
<td>$49.2K</td>
<td align="right">83</td>
<td>14</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$0.49</td>
<td>$0.31</td>
<td>$0.49</td>
<td>$290.00</td>
<td>$48.5K</td>
<td align="right">115</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About Carvana</h3>
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
In light of the recent options history for Carvana, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Carvana's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 514,090, the CVNA's price is up by 2.31%, now at $260.86. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 83 days.</li>
</ul>
<h3>What Analysts Are Saying About Carvana</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $269.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from JMP Securities persists with their Market Outperform rating on Carvana, maintaining a target price of $320. 
&#x2A; An analyst from Morgan Stanley upgraded its action to Equal-Weight with a price target of $260. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Carvana, which currently sits at a price target of $300. 
&#x2A; An analyst from Baird has decided to maintain their Neutral rating on Carvana, which currently sits at a price target of $240. 
&#x2A; An analyst from Piper Sandler persists with their Neutral rating on Carvana, maintaining a target price of $225. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Carvana with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

CVNA

Smart Money Is Betting Big In CVNA Options

Canadian cannabis producer Entourage Health Corp. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#TSXV">ENTG</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ETRGF#OTCQX">ETRGF</a>) (FSE: 4WE) announced on Friday its third quarter financial results for the three months ended Sept. 30, 2024.
The company reported an 8% year-over-year increase to CA$9.5 million ($6.8 million) in net revenue for the period. Sequentially, net revenue <a href="https://www.benzinga.com/markets/cannabis/24/08/40577400/entourage-cannabis-co-s-q2-revenue-drops-nearly-9-yoy-ceo-optimistic-about-future-opportunities">increased by 2.1%</a>
George Scorsis, the company's CEO and chair, said the revenue growth is a result of a strategic shift into different markets. The move allowed the company to "diversify and tap into new opportunities," Scorsis said.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/05/39037667/entourage-health-cannabis-reports-9-yoy-increase-in-q1-revenue-positive-ebitda-and-substantial-g">Entourage Health Cannabis Reports 9% YoY Increase In Q1 Revenue, Positive EBITDA And &#8216;Substantial Growth&#8217;</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Q3 2024 Financial Results</h3>
<ul>
<li>Gross profit was CA$2.9 million, up from CA$2.4 million in the prior year's period.</li>
<li>Gross margin improved to 30%, up from 27% in the same period last year, driven by enhanced operational efficiencies and automation.</li>
<li>Net loss and comprehensive loss dropped to CA$8.4 million year-over-year from nearly CA$10 million.</li>
<li>EBITDA was a loss of CA$1 million, representing a 70% improvement compared to a loss of CA$3.4 million in the third quarter of fiscal 2023.</li>
<li>Selling, general and administrative expenses were reduced by 32%, reflecting savings from restructuring and discontinued activities in 2023.</li>
</ul>
<h3 class="wp-block-heading">What's Next</h3>
&#8220;With the holidays approaching, we are excited to introduce several highly anticipated products, demonstrating our commitment to delivering meaningful and timely offerings,&#8221; Scorsis said. &#8220;As the cannabis industry stabilizes, our team's creativity and operational focus on optimizing the business will position us as a market leader." 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/04/38525232/cannabis-co-entourage-health-reports-126-yoy-increase-in-2023-gross-profit-cuts-losses-significa">Cannabis Co. Entourage Health Reports 126% YoY Increase In 2023 Gross Profit, Cuts Losses Significantly</a></li>
</ul>
ETRGF Price Action
Entourage's shares traded 18.75% higher at $0.0048 per share at the time of writing on Friday.

Earnings

ETRGF

TSXV:ENTG

Canadian Cannabis Co. Entourage Health Shares Spike On 8% YoY Q3 Revenue Growth, Reduced Losses

A new Senate <a href="https://www.hsgac.senate.gov/wp-content/uploads/2024.11.25-Majority-Staff-Report-The-Skys-the-Limit-The-Rise-of-Junk-Fees-in-American-Travel-1.pdf">report</a> has shed light on just how much money airlines are making off add-ons like seat and <a href="https://www.benzinga.com/markets/equities/24/06/39288640/southwest-airlines-free-bag-policy-under-pressure-after-elliotts-1-9b-stake">baggage fees</a>. And it&#8217;s a lot: $12.4 billion from seat selection fees alone between 2018 and 2023. And now, lawmakers and the Biden administration are saying enough is enough.
Sen.<a href="https://www.benzinga.com/news/23/12/36323074/tesla-executive-says-senator-blumenthals-autopilot-claims-misinformed-invites-meeting-with-safety-te"> Richard Blumenthal</a>, who chairs the Senate&#8217;s Permanent Subcommittee on Investigations, recently revealed the findings. Blumenthal said that airlines have been exploiting passengers with what he calls &#8220;junk fees,&#8221; like extra charges for picking your seat – whether it's just for a standard aisle or window spot or the more spacious, extra legroom seats.&nbsp;
Don't Miss:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
</ul>
These fees have become a huge source of income for big airlines like American, Delta, United, Frontier and Spirit, bringing in billions. At the same time, passengers deal with higher prices and a more confusing booking experience.
Seat fees increased substantially over the five years. Per the report, Frontier Airlines, for example, raised the price of its most expensive extra legroom seat from $50 in 2018 to $141 in 2023. Spirit Airlines similarly escalated its maximum seat fee for extra legroom from $71 in 2018 to $299 in 2023. Spirit&#8217;s Big Front Seats, the airline&#8217;s most premium seating option, saw an even bigger rise, going from $140 to $899 over the same time frame.
Blumenthal argues that these charges aren't tied to any real cost to the airline. The report found that the airlines couldn't clearly show what it costs them to offer seat assignments. This suggests that the prices aren&#8217;t based on the service provided but are another way to bump up revenues. And if you&#8217;ve ever booked a flight and faced charges just to make sure you sit next to your kid, you know how frustrating it can be.
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!</a>
The Biden administration also addresses these fees, which they see as unfair burdens on travelers. As part of his larger campaign against &#8220;junk fees&#8221; in various sectors, including banks, hotels and other services that tack on additional fees, President Biden has spoken out against these charges. <a href="https://www.benzinga.com/government/24/08/40112052/family-friendly-skies-proposal-aims-to-end-airline-seating-fees-for-parents-with-kids">Families shouldn&#8217;t have to pay more</a> just to sit together, so the administration wants to make flying easier.
The Senate&#8217;s investigation also highlighted other questionable practices. For example, airlines like Frontier and Spirit have been paying gate agents to enforce baggage rules strictly, leading to passengers being charged extra for their bags and sometimes even missing flights because of it. Between 2022 and 2023 alone, these gate agents received around $26 million in commissions for catching passengers out on baggage size, according to the Majority Report.
Trending: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
Airline executives from the major carriers are set to testify at a Senate hearing on Dec. 4 to answer for these practices. The hearing, &#8220;The Sky&#8217;s the Limit – New Revelations About Airline Fees,&#8221; is anticipated to probe the reasons behind the exorbitant prices and whether there is any real basis for them.
The airlines, of course, have defended their actions. As CNBC reports, Airlines for America, a trade group representing the biggest U.S. carriers, pushed back, saying that the Senate report doesn't &#8220;understand the value the highly competitive U.S. airline industry brings to customers and employees.&#8221; They also claim that today&#8217;s more competitive pricing structure makes flying more affordable. However, critics point out that the complexity and rising costs of add-ons like seat fees often make trips <a href="https://www.benzinga.com/markets/equities/24/07/40030510/us-appeals-court-halts-bidens-airline-fee-disclosure-rule-saying-it-will-irreparably-harm-carrie">more expensive than they initially appear</a> when you first see the ticket price.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>

Startups

In 5 Years, Airlines Made $12.4 Billion From Seating Fees Alone. Senate And Biden Admin Say These 'Junk Fees' Must Stop

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) with a Buy and maintains $11 price target.

Reiteration

CLGN

HC Wainwright & Co. Reiterates Buy on CollPlant Biotechnologies, Maintains $11 Price Target

DA Davidson analyst Linda Bolton Weiser maintains Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) with a Neutral and raises the price target from $70 to $87.

PLNT

DA Davidson Maintains Neutral on Planet Fitness, Raises Price Target to $87

Laser Photonics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) launched a research and development initiative to create laser solutions for pharmaceutical tablet drilling, wafer <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42241997/laser-photonics-launches-r-d-initiative-to-accelerate-innovation" rel="noreferrer noopener">scribing, and semiconductor marking</a>.
Laser Photonics is targeting pharmaceuticals, wafers, and semiconductors through its latest R&amp;D initiative. Following its&nbsp;recent acquisition&nbsp;of&nbsp;Control Micro Systems, the company is committing resources to several new engineering projects to continue advancing its newly acquired laser systems.&nbsp;
In pharmaceuticals, the company plans to advance Control Micro Systems&#8217; tablet drilling and marking system for time-release medications.
This Class I automated CO2 laser system includes a custom tablet fixture, fume extraction, and machine vision inspection for quality control, offering an effective anti-counterfeiting solution.
Laser technology for wafer serialization involves marking, scribing, and lapping silicon and related compound wafers.
The company plans to enhance Control Micro Systems' multi-station system, designed for wafers up to 300 mm wide and 300–800 microns thick, featuring robotic wafer positioning.
This technology supports production and tracking for applications such as consumer electronics, solar panels, LEDs, MEMS devices, and optoelectronic components.
Laser Photonics will also advance Control Micro Systems&#8217; semiconductor laser marking system, featuring a high-precision ultraviolet laser and galvanometer scanhead for rapid fiducial recognition.
This system creates small, permanent markings on IC mold compounds and ceramics with minimal heat, preventing damage to components. Integrated machine vision ensures accurate chip positioning and marking alignment.
This week, Laser Photonics opened pre-orders for its upcoming CleanTech Industrial <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42210836/laser-photonics-commences-pre-orders-for-industry-leading-pulsed-laser-cleaning-system" rel="noreferrer noopener">Roughening Laser 3060 (CTIR-3060)</a>.
Price Action: LASE shares are up 0.36% at $5.63 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42244572" target="_blank" rel="noreferrer noopener">Cannabis-Focused RIV Capital Reports 186% YoY Surge In Q3 Revenue Ahead Of Major Merger That Will Cover 25% Of US Population</a></li>
</ul>
Image via Unsplash.

Small Cap

LASE

From Pills To Wafers: Laser Photonics Unveils R&D Initiative For Anti-Counterfeiting And High-Tech Manufacturing

CLSA analyst Baden Moore initiates coverage on Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) with a Underperform rating.

Initiation

CLSA Initiates Coverage On Newmont with Underperform Rating

Wedbush analyst Daniel Ives reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Outperform and maintains $300 price target.

AAPL

Wedbush Reiterates Outperform on Apple, Maintains $300 Price Target

WIIM

APVO

Aptevo Therapeutics shares are trading lower after the company announced a 1-for-37 reverse stock split.

Analyst Jason Butler from JMP Securities reiterated a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report) and keeping the price target at...

Buy Rating Affirmed for Vigil Neuroscience Inc. as FDA Lifts Clinical Hold and Phase 1 Trials Show Promise

Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated price ta...

Buy Rating Affirmed for Vigil Neuroscience Inc Amid Promising Alzheimer's Treatment Potential

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report) today and set a price target of $11...

Stifel Nicolaus Sticks to Its Buy Rating for Vigil Neuroscience Inc (VIGL)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vanda (VNDA – Research Report) and Vigil Neuroscienc...

Analysts Are Bullish on Top Healthcare Stocks: Vanda (VNDA), Vigil Neuroscience Inc (VIGL)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vigil Neuroscience Inc (VIGL – Research Report), Qiagen (QGEN – R...

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Qiagen (QGEN) and LifeMD (LFMD)

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on VIGL stock, giving a Buy rating on November 8. Graig Suvannavejh...

Bullish Outlook on Vigil Neuroscience Inc. Amid Promising Clinical Data and Unique TREM2 Biology Focus

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report), Vigil Neuroscience Inc (...

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Vigil Neuroscience Inc (VIGL) and Biohaven Ltd. (BHVN)

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated price ta...

Promising Potential of Vigil Neuroscience's VG-3927 in Alzheimer's Treatment with a Buy Rating and $17 Price Target

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on VIGL stock, giving a Buy rating yesterday. Graig Suvannavejh has...

Optimistic Buy Rating for Vigil Neuroscience Amid Market Overreaction

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IN8bio (INAB – Research Report), Vigil Neuroscience ...

Comments

Vigil Neuroscience

Notizie

Ultime notizie per Vigil Neuroscience (NASDAQ:VIGL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO